Pancreatitis as a Consequence of Endoscopic Retrograde Cholangiopancreatography: A Comprehensive Review of the Literature from a Case Report
Main Article Content
Abstract
Post ERCP pancreatitis, also known as post-endoscopic retrograde cholangiopancreatography pancreatitis, is a potentially serious complication that can occur after this endoscopic procedure. It is characterized by acute inflammation of the pancreas, triggered by the manipulation and trauma induced during ERCP. This clinical condition manifests with severe abdominal pain, nausea, vomiting, bloating and fever. It varies in severity and may be associated with significant complications, such as pancreatic pseudocysts, abscesses, systemic infections, gastrointestinal bleeding, bile duct and pancreatic duct obstruction, as well as the possibility of pancreatic necrosis.
Management involves a multidisciplinary approach, including supportive measures, analgesic therapy and, in severe cases, hospitalization and additional procedures such as percutaneous drainage or surgery. To prevent this complication, precautions are recommended during ERCP, such as the use of aseptic techniques, careful handling of endoscopic instruments and prophylactic use of medications. In conclusion, post-ERCP pancreatitis requires early diagnosis, an appropriate therapeutic approach and close surveillance to avoid adverse consequences and promote patient recovery.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Cotton PB, Garrow DA, Gallagher J, et al. Risk factors for complications after ERCP: A multivariate analysis of 11,497 procedures over 12 years. Gastrointest Endosc 2009; 70:80-8. DOI: 10.1016/j. gie.2008.10.039.
II. Loperfido S, Angelini G, Benedetti G, et al. Major early complications from diagnostic and therapeutic ERCP: A prospective multicenter study. Gastrointest Endosc 1998; 48:1-10. DOI: 10.1016/ S0016-5107(98)70121-X
III. Masci E, Toti G, Mariani A, et al. Complications of diagnostic and therapeutic ERCP: A prospective multicenter study. Am J Gastroenterol 2001; 96:417-23. DOI: 10.1111/j.1572-0241.2001.03594.x
IV. Vandervoot J, Soetikno RM, Tham TC, et al. Risk factors for complications after performance of ERCP. Gastrointest Endosc 2002;56:652-6. DOI: 10.1016/S0016-5107(02)70112-0
V. Elmunzer BJ, Scheiman JM, Lehman GA, et al. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med 2012;366:1414-22. DOI: 10.1056/NEJMoa1111103.
VI. Fazel A, Quadri A, Catalano MF, et al. Does a pancreatic duct stent prevent post-ERCP pancreatitis? A prospective randomized study. Gastrointest Endosc 2003;57:291-4. DOI: 10.1067/mge.2003.124.
VII. Smithline A, Silverman W, Rogers D, et al. Effect of prophylactic main pancreatic duct stenting on the incidence of biliary endoscopic sphincterotomy-induced pancreatitis in high-risk patients. Gastrointest Endosc 1993;39:652-7. DOI: 10.1016/S0016-5107(93)70217-5
VIII. Sofuni A, Maguchi H, Itoi T, et al. Prophylaxis of post-ERCP pancreatitis by an endoscopic pancreatic spontaneus dislodgement stent. Clin Gastroenterol Hepatol 2007;5:1339-46. DOI: 10.1016/j. cgh.2007.07.008.
IX. Tarnasky PR, Palesch YY, Cunningham JT, et al. Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction. Gastroenterology 1998;115:1518-24. DOI: 10.1016/S0016-5085(98)70031-9
X. Ito K, Fujita N, Noda Y, et al. Can pancreatic duct stenting prevent post-ERCP pancreatitis in patients who undergo pancreatic duct guidewire placement for achieving selective biliary cannulation? A prospective randomized controlled trial. J Gastroenterol 2010;45:1183-91.
DOI: 10.1007/s00535-010-0268-7